Relates to the classification of the drug xylazine as a schedule I controlled substance, and to the criminal sale and possession of xylazine or preparations, compounds, mixtures or substances containing xylazine.
Summary
This bill would classify xylazine as a Schedule I controlled substance under New York’s Public Health Law. Xylazine is added to the state’s controlled substance schedules, and the Penal Law is amended to create a new category, “adulterant depressant,” for xylazine. The bill then updates multiple drug offense provisions so that criminal sale and possession statutes that currently apply to narcotic drugs would also apply to xylazine-containing preparations, compounds, mixtures, or substances.
In practical terms, the bill expands New York’s drug enforcement framework to cover xylazine at several offense levels, including possession and sale offenses tied to specific aggregate weights and intent to sell. The measure would make xylazine subject to the same kinds of criminal penalties that apply to certain controlled substances, thereby broadening prosecutorial tools against trafficking or distribution of xylazine or mixtures containing it. The bill takes effect immediately upon enactment.
Impact
The bill amends the Public Health Law’s Schedule I and multiple Penal Law sections governing criminal possession and sale of controlled substances. It would add xylazine to the state’s controlled substance list and insert “adulterant depressant” into several drug offense provisions, extending existing narcotics-based penalties to xylazine-related conduct. Affected parties would include individuals accused of possessing or selling xylazine, law enforcement, prosecutors, and courts applying drug offense classifications and sentencing provisions.
Sentiment
There is no recorded committee transcript or vote history in the provided materials, so no formal debate or roll-call sentiment is available. Based on the bill’s text and caption, the measure appears to be framed as a public health and enforcement response to the presence of xylazine in illicit drug supply chains. The overall posture of the bill is punitive and regulatory, indicating support for stronger control of the substance rather than a treatment-oriented approach.
Contention
The main point of contention likely concerns whether xylazine should be treated as a Schedule I controlled substance and whether criminal penalties are the appropriate response to its use and distribution. Supporters would likely emphasize enforcement against adulterated drug supplies and the risks posed by xylazine, while opponents may argue that criminalization could sweep too broadly, especially where xylazine is found in mixtures or where users are affected by contamination rather than intentional trafficking. No specific stakeholder positions are documented in the provided record.
Provides that when a drug is designated or rescheduled by the federal government, it shall be deemed scheduled under NYS law automatically, without further action by the commissioner.